Tissuemed is pleased to announce the first clinical use of TissuePatch™ in China following CFDA approval of the product line back in May.
The case, a thoracic procedure was undertaken successfully by surgeons working at a leading hospital in Sichuan province, southwest China.
For Tissuemed, CEO David Mandley commented; “this is a notable event as we prepare to launch TissuePatch™ in China. It’s great to have positive feedback not long after obtaining CFDA approval for the product range.”
For further information about the use of TissuePatch for air leak prevention visit the Tissuemed website or contact us directly via info@tissuemed.com